Generic Medication May Help Breast Cancer Therapy Adherence

Share this content:
Cost a key factor for women to maintain hormone treatment regimen in breast cancer therapy.
Cost a key factor for women to maintain hormone treatment regimen in breast cancer therapy.

Access to generic aromatase inhibitors (AIs) improves the chances that breast cancer patients will stick with their drug treatment, according to research published in the Journal of the National Cancer Institute.

The study included 5,511 women. All were 50 years of age or older and had early-stage breast cancer that was hormone receptor-positive. The women in the study all had surgery to remove their breast cancer. After surgery, they were prescribed AIs.

Even though AIs significantly reduce the risk of disease recurrence in patients with this type of breast cancer, many women don't take their medications as directed, the researchers said.

The patients in the study were followed for two years. The investigators found that women who took generic AIs were 50 percent more likely to adhere to their drug therapy than those who took brand-name AIs.

RELATED: For Patients With Advanced Triple Negative Breast Cancer, Eribulin May Improve Overall Survival

"Our findings suggest that more effort should be made to reduce out-of-pocket costs for these potentially life-saving medications. This is especially important given the rapid increase of expensive oral cancer therapies," study leader Dawn Hershman, M.D., an associate professor of epidemiology at Columbia University Medical Center in New York City, said in a hospital news release.

"Cost is not the only reason. But it can intensify other factors such as side effects. Up to 40 percent of women taking AIs experience joint stiffness. If you add a high copayment to the mix, that's often enough to make them discontinue therapy."


  1. Hershman, Dawn L., et al. "The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer." Journal of the National Cancer Institute. doi: 10.1093/jnci/dju319. August 22, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs